

Date:- April 23, 2025

To, The Manager, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, C-1, Block – G, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, BSE Limited, 1 st Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001.
Scrip Code – LINCOLN	Scrip Code – 531633

Dear Sir/Ma'am,

Sub: Initial Large Corporate Disclosure - FY 2025-26

Ref: SEBI Circular No: SEBI/HO/DDHS/DDHSRACPOD1/P/CIR/2023/172 dated October 19, 2023

With reference to the above circular, we wish to inform that, our Company does not fall under the category of Large Corporates (LC) as on 31st March 2025, as per the framework provided in the said Circular since the specified criteria are not applicable to us.

The undertaking as required under the said circular is enclosed as ("**Annexure -A**").

This is for your information and records.

Thanking you,

For, Lincoln Pharmaceuticals Limited,

For, Lincoln Pharmaceuticals Limited,

Trusha Shah
Company Secretary & Compliance Officer

Darshit Shah
Chief Financial Officer

Encl.: As Above

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India
Phone : +91-79-4107 8000 | **Fax :** +91-79-4107 8062 | **CIN** L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | **Website :** www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta. : Kalol, Dist. Gandhinagar, (Guj.) | **Phone :** +91-79-49135000 | **E-mail :** khatraj@lincolnpharma.com



Annexure - A

Initial Disclosure to be made by an entity identified as a Large Corporate to be submitted to the Stock Exchange(s) within 30 days from the beginning of the FY 2025-26)

SI. No	Particulars	Details
1.	Name of the company	Lincoln Pharmaceuticals Limited
2.	CIN	L24230GJ1995PLC024288
3.	Outstanding borrowing of company as on 31st March (in Rs. crore)	Not applicable
4.	Highest credit rating during the previous FY along with name of the CRA	Not applicable
5.	Name of stock exchange in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	Not applicable

We confirm that we are not a Large Corporate as per the applicability criteria given under the SEBI Circular SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023. Kindly take note of the above intimation on your records.

Thanking you,

For, Lincoln Pharmaceuticals Limited,

For, Lincoln Pharmaceuticals Limited,

Trusha Shah
Company Secretary & Compliance Officer
Contact Details: 079-41078081

Darshit Shah
Chief Financial Officer
Contact Details: 079-41078048

Date: April 23, 2025